13 results
8-K
EX-99.1
MRSN
Mersana Therapeutics Inc
28 Feb 24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
7:07am
and $3.7 million of external costs related to the wind-down of UpRi-related development activities. The year-over-year decline in R&D expenses was primarily
8-K
2n18 6qrjf4ld9tjsd
27 Jul 23
Results of Operations and Financial Condition
7:32am
8-K
EX-99.1
880xtn3c21wwm71
27 Jul 23
Results of Operations and Financial Condition
7:32am
8-K
1ctd96hjeckmsuigs
4 Jan 19
Termination of a Material Definitive Agreement
7:05am
- Prev
- 1
- Next